MIL Submissions Engine

Source: The Conversation – UK – By Giacomo Melli, PhD candidate in sociology, University of Oxford

Imagine society as a ladder with ten rungs. Where would you place yourself? That answer reflects your subjective social status – where you see yourself in society. Importantly, this is not necessarily reflective of where you actually are. Subjective social status matters as it shapes what you believe, how you behave, and, as my new study shows, how much you care about economic inequality.

These days, economic inequality is hard to ignore. In the UK, the richest 10% of households holds nearly half of all wealth, while millions struggle to make ends meet.

My research asked: why do some people support reducing inequality while others don’t?

Take two middle class professionals with similar jobs and incomes. One supports higher taxes on the wealthy, the other doesn’t. Why the difference? It’s not just their actua class position. What matters is where they feel they stand in society – their subjective social status.

My research analysed survey data on more than 51,000 people from 25 countries where respondents placed themselves on a ten-rung ladder representing society. This simple question – about how people feel they rank socially – turns out to be a powerful predictor of support for redistribution, such as progressive taxation or government efforts to reduce income inequality.

You might assume that views on redistribution boil down to income: those struggling financially want the government to help reduce inequality, while those who are doing well want to keep things as they are. But what really matters is where people feel they stand compared to others, regardless of their actual income or job.

As the sociological theory known as the Thomas theorem puts it: “If people define situations as real, they are real in their consequences.” These consequences can also affect politics – how people perceive their social standing can shape what policies (and parties) they support.

Where do you think you are?

My research found that people who feel at the bottom of the social ladder tend to support income redistribution, regardless of how unequal their country actually is. That might seem obvious.

But what’s striking – and what the research also shows – is how often people’s perceptions don’t match their economic reality. One in five who place themselves in the top third are in fact working class, while one in five people who see themselves in the bottom third of society are actually high income earners in their country. People’s perceptions of where they stand often don’t match reality because they rely on personal background, upbringing and comparisons with peers or social circles.

You might expect those who feel near the top of society to oppose redistribution, especially in countries where inequality is high. Yet the evidence tells a different story. People behave very differently depending on how unequal their society is.

In countries where income inequality is high, those who feel privileged are often more supportive of redistribution. This doesn’t happen in countries where inequality is low. My findings show that, for example, someone who feels near the top in the US (an unequal country) is 31% more likely to support government action to reduce inequality than their counterpart in more equal Denmark.

This suggests that “wealthy” people’s attitudes aren’t just about protecting their own interests. Something else is at play.

Fear and altruism

One possible answer lies in two feelings: fear and altruism. Those who feel socially well off don’t live in a vacuum, they notice when inequality is high around them. Whether out of fear for their own safety, altruism for those struggling or both, these feelings can lead even the privileged to support government efforts to reduce inequality.

Why should those who feel at the top of society in low-inequality countries worry? They think they are doing well, and they can see that society around them is also functioning reasonably well.

People respond not only to their material conditions, but to how they see themselves and the context around them. Even those who feel they’re doing well may support redistribution if they believe growing inequality could threaten the system.

This research reveals something crucial about how politics works in democratic societies. Politics is about how people see themselves, not just their income or class. This matters beyond redistribution. It also affects populist attitudes, electoral participation and support for far-right parties.

This insight helps explain why some middle-class voters might back policies that don’t seem to benefit them, and why opinions vary so much between similar countries. As inequality keeps shaping political debates worldwide, understanding these feelings becomes key to making sense of contemporary politics. At the end of the day, it’s perception, not just reality, that drives the politics we see.

Giacomo Melli does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

– ref. Where you think you are in society (not where you actually are) matters for how you think about inequality – https://theconversation.com/where-you-think-you-are-in-society-not-where-you-actually-are-matters-for-how-you-think-about-inequality-259715

Source: The Conversation – UK – By Dan Baumgardt, Senior Lecturer, School of Physiology, Pharmacology and Neuroscience, University of Bristol

Walk into any health store, scroll through TikTok, or browse the shelves of your favourite beauty retailer, and you’ll be met with a familiar promise: that a pill, powder or potion could be the secret to glowing skin, boosted energy, or even inner “detoxification.” Among the most hyped are chlorophyll – the green pigment in plants now found in trendy waters and tinctures – and collagen, the protein hailed as the holy grail for youthful skin and strong joints.

But how much of the buzz is backed by science? And how much is just clever marketing dressed up in green juice and glossy packaging?

Let’s take a closer look to explore what they actually do, what the evidence says, and whether your money (and hopes) might be better spent elsewhere.

Chlorophyll

Dark leafy greens like kale and cavolo nero are well known for boosting levels of essential nutrients such as iron, folate and beta-carotene. They’re also rich in chlorophyll – the pigment that plays a key role in photosynthesis, the process by which plants use sunlight to produce glucose and oxygen.

Some wellness influencers, including Gwyneth Paltrow and Kourtney Kardashian-Barker, have popularised chlorophyll water as part of their daily health routines. Both promote it through their respective wellness brands – Goop and Poosh – touting a range of supposed benefits, from reducing body odour to supporting detoxification. One of the more persistent claims is that chlorophyll – in water or supplement form – can “oxygenate” the blood.

But as Ben Goldacre – physician, academic and prominent critic of pseudoscience – has pointed out, that claim doesn’t quite hold up. The human body, unlike a plant leaf, isn’t flooded with sunlight. And without light, chlorophyll simply can’t perform photosynthesis in the gut or bloodstream. It can’t generate oxygen internally – no matter how green your smoothie.

So what does chlorophyll actually do? Aside from turning plants (and your poo) a vivid shade of green, its core function is to trap sunlight and convert water and carbon dioxide into glucose and oxygen. Cast your mind back to GCSE biology and the familiar photosynthesis equation scribbled across the whiteboard.

Through this process, plants generate food for themselves and for animals – while releasing oxygen into the atmosphere. It’s a pathway fundamental to life on Earth. But since we breathe in oxygen and eat carbohydrates, we’ve managed to thrive without chlorophyll. And for it to work in humans the way it does in plants, it would surely need to be present in our skin – effectively turning us into the Wicked Witch of the West.

So what about those wider health claims? Supplement packaging for chlorophyllin – a semi-synthetic, water-soluble form of chlorophyll thought to be more active – often promises detoxification, glowing skin, improved wound healing and even better body odour.

The suggested mechanisms? Chlorophyll may inhibit bacterial growth or neutralise foul-smelling compounds in the gut. It’s also been proposed as a free radical scavenger – mopping up the unstable molecules generated by toxins or metabolism that can damage tissues.

The evidence is mixed. A few (much older) studies suggest chlorophyllin can reduce the odour of faeces and flatulence, although it might also turn them green. There’s weaker evidence when it comes to halitosis or body odour. Research supporting its role as an antioxidant is limited, and the buzz around weight loss is largely anecdotal. Realistically, any benefit in that department likely comes from a diet rich in greens – low in fat and high in fibre – rather than chlorophyll alone.

Where things get more promising is in wound care. Chlorophyll-based dressings have been investigated for their ability to accelerate healing and reduce odours from infected wounds.

---

Read more:
How to treat a wound – without using superglue, grout or vodka, like some people

---

Collagen

But chlorophyll isn’t the only so-called “miracle” substance being sold to the wellness crowd. Take collagen – arguably even more popular than any green powder or superfood pill.

Collagen is a protein and a natural component of connective tissue found throughout the body. It gives strength and structure to the skin, bones, ligaments, blood vessels – even the heart and lungs. Without enough collagen – or in conditions where collagen production is impaired, such as Ehlers-Danlos syndrome – tissues can become fragile, prone to damage or slow to heal.

All the more reason, then, to make sure our bodies can produce it. Collagen is made from amino acids – the building blocks of protein – so eating enough protein is essential. Vitamin C also plays a vital role, helping the body synthesise collagen from those amino acids.

But do we really need to supplement it? What does the evidence say? Some studies suggest oral collagen supplements may help improve skin appearance, support joint health, increase bone strength, and enhance muscle mass. But there’s no convincing evidence that they promote weight loss or treat cardiovascular or autoimmune conditions – despite the lofty promises made by some brands.

Topical collagen products are even more widespread, but their scientific backing is thinner. Collagen molecules are generally too large to be absorbed through the skin, meaning they’re unlikely to have any meaningful impact on wrinkles. At best, they may hydrate the surface and offer a temporary plumping effect.

In short, the research is patchy – encouraging in some areas, inconclusive in others. And when it comes to supporting your body’s natural collagen production, there may be more effective (and less expensive) options. Foods such as chicken, fish, eggs and bone broth ensure a good protein intake. So too are collagen-supporting micronutrients, including vitamin C, copper and zinc.

---

Read more:
Bone broth is hyped by celebrities and hailed as a wellness superfood – here’s what the science says

---

So unless you’re Poison Ivy from Batman (who, to be fair, looks fantastic), you probably don’t need to load up on chlorophyll. And unless your diet is lacking, you don’t need to shell out for collagen powders or creams either.

Love the skin you’re in. It’s better than turning green like Elphaba from Wicked.

Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

– ref. From clear skin to detoxing, chlorophyll and collagen supplements promise a lot, but what does the science say? – https://theconversation.com/from-clear-skin-to-detoxing-chlorophyll-and-collagen-supplements-promise-a-lot-but-what-does-the-science-say-261210

Source: The Conversation – UK – By Joseph Janes, Senior Lecturer in Criminology, Swansea University

In the blistering heat of Freetown, Sierra Leone, young men gather on street corners, their limbs swollen, eyes glazed. They are the victims of kush, a cheap and deadly synthetic drug sweeping the country.

But kush is not an isolated tragedy. From the townships of apartheid South Africa to the 21st-century streets of the UK, synthetic drugs have a long history of flourishing in places where society has abandoned its most vulnerable.

Kush first appeared in Sierra Leone around 2016, but its spread in recent years has been nothing short of catastrophic. Between 2020 and 2023, psychiatric admissions linked to the drug skyrocketed to a reported 1,865 cases at the country’s only psychiatric hospital.

The drug claims mostly young men between the ages of 18 and 25, whose bodies are ravaged by kush’s toxic effects. Doctors in Freetown estimate that hundreds of users have died from organ failure caused by the drug in recent months.

Sierra Leone’s president, Julius Maada Bio, branded kush a “death trap” and declared a national emergency. The drug, he says, represents an “existential crisis” for the nation.

Kush is both cheap and easily accessible, sold openly on the streets for as little as 20 pence per joint. But for those hooked on it, the cost can climb to £8 a day. This is a staggering sum in a country where the average income barely exceeds £4,000 a year.

The drug’s ingredients are equally chilling. A mix of cannabis, synthetic opioids like fentanyl, formalin (used in embalming) and, according to some reports, ground human bone, it’s a concoction that speaks to the bleakness of life for those who turn to it.

Kush’s grip on Sierra Leone is not a random phenomenon but a symptom of a much deeper problem. The drug has become a chemical escape for people who see no viable future for themselves.

For those living in poverty and experiencing hunger, kush offers something that life in Sierra Leone often cannot: temporary relief from trauma and despair. It’s not a recreational indulgence but survival in a country where many face daily battles just to get by.

The drug’s rise follows a pattern seen in other parts of the world, where synthetic substances fill the void left by broken systems.

Apartheid South Africa

The situation in Sierra Leone echoes a chilling chapter from South Africa’s apartheid era. In the 1980s, methaqualone, a synthetic sedative-hypnotic drug – sold as quaalude or mandrax – became widely used in the townships, particularly among Black communities.

Often smoked alongside cannabis in a mix known as the “white pipe”, it became a cheap, sedative drug much like kush in Freetown today.

The apartheid government didn’t just turn a blind eye to its widespread use but deliberately encouraged it. Under the secretive Project Coast, the government’s chemical and biological warfare programme, scientists developed large quantities of methaqualone, ostensibly for crowd control and incapacitation.

Methaqualone was not officially declared a weapon. But evidence compiled by the UN suggests it was developed and stockpiled in prototype delivery systems that were intended to incapacitate without killing, then deployed quietly among the dissenting population.

---

Read more:
Addicted: how the world got hooked on illicit drugs – and why we need to view this as a global threat like climate change

---

The parallels with kush are undeniable. Both are chemically produced, highly addictive depressants offering cheap and easily accessible sedation to marginalised populations. These types of drug do not just affect individuals but serve to suppress entire communities under the weight of structural violence.

In South Africa, methaqualone was weaponised by the state as a means of control, while in Sierra Leone, kush has emerged in areas abandoned by the government. In both cases, the effect is the same: a drug-fuelled stasis that deepens despair and maintains a status quo of social neglect.

It’s a pattern where a synthetic depressant materialises in places where no other social or economic medicine exists, sedating not only bodies but resistance and possibility.

Spice in the UK

This pattern of synthetic drugs as a response to social decay is not confined to Africa. In the UK, synthetic drugs such as spice have become more common over the past decade, especially among homeless people and prisoners. Described as a “zombie drug” for its paralysing effects, spice is often used not for pleasure but to escape hunger, cold and trauma.

A 2023 study among the UK’s homeless population found that nearly 70% of participants, aged 18-64, used synthetic drugs such as spice to escape the harsh realities of homelessness. Many reported adverse effects that led to hospitalisation.

In many British towns and cities, it has become common to see users slumped on pavements or convulsing in parks, echoing the scenes from Sierra Leone’s kush hotspots.

This serves as a stark reminder that synthetic drugs are not an isolated issue. They are a global crisis playing out in different forms but with the same underlying causes.

Synthetic drugs like kush, methaqualone and spice are symptoms of deeper systemic failures. They thrive where housing is unstable, unemployment is rampant and healthcare is out of reach. Addressing the crisis requires more than just cracking down on drug use. It demands a radical shift in how we treat the most vulnerable in our society.

---

Read more:
‘There has never been a more dangerous time to take drugs’: the rising global threat of nitazenes and synthetic opioids

---

In Sierra Leone, this means investing in youth employment, improving nutrition and strengthening mental health services. In the UK, it calls for restoring funding to housing and substance use services, and recognising that stable shelter and social support are fundamental to recovery, not rewards for abstinence.

If we are serious about tackling this problem, we need to move beyond punishment and focus on addressing the root causes of addiction. Only by investing in social care and harm reduction can we hope to break the cycle of sedation and despair.

Joseph Janes does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

– ref. Synthetic drugs are having devastating effects around the world, from Sierra Leone to the UK – https://theconversation.com/synthetic-drugs-are-having-devastating-effects-around-the-world-from-sierra-leone-to-the-uk-262746

Source: The Conversation – UK – By Brian Brivati, Visiting Professor of Contemporary History and Human Rights, Kingston University

Armenia and Azerbaijan signed a peace framework in Washington on August 8 after nearly four decades of conflict. The two nations, long divided over territorial disputes, committed to end hostilities, normalise relations and respect each other’s territorial integrity.

Brokered by the US president, Donald Trump, it had all the glitzy appearance of a comprehensive peace agreement. But in reality, it is merely a move in that direction. There are still many ways it could break down.

The decision of Armenia’s prime minister, Nikol Pashinyan, to pursue peace is politically risky. Armenian military defeats to Azerbaijan in 2020 and 2023, and the loss of the disputed Nagorno-Karabakh region, left deep scars.

Many Armenians feared concessions would legitimise Azerbaijan’s military gains or erode national sovereignty. Diaspora voices warned of “rewarding aggression” and ignoring the rights of displaced Karabakh Armenians. Yet Pashinyan pressed ahead, arguing a diplomatic settlement was the only route to security and prosperity.

His pivot away from relying on Russia – a former security guarantor whose credibility in Armenia has crumbled after failing to stop Azerbaijan from seizing Nagorno-Karabakh – signals a profound geopolitical shift. The US is now the guarantor of security, ending the Minsk process that has been working to resolve the conflict since 1994.

Sovereignty secured

One of the thorniest issues was Azerbaijan’s demand for a land route across southern Armenia to connect with its Nakhchivan exclave. Armenians feared this could mean ceding control of national territory. The US-brokered agreement resolves the dispute.

Armenia retains full sovereignty and jurisdiction over any new route. All transport links will operate under Armenian law, with Armenian customs and security in place. This is a marked improvement on the vague “unimpeded” transit clause in the 2020 ceasefire, which left room for dispute.

By enshrining sovereignty in the text, Armenia can reassure its public that the corridor is not an extraterritorial carve-out, but a transport link it is hosting. However, the corridor runs close to the Iranian border. And the Iranians, also pushed out of their influential role in Armenia by this deal, have already rejected it.

Following its recent war with Israel, Iran is perhaps too weak to stop the project from starting. But it could represent a threat to the security of companies involved in the route’s construction.

The transit corridor, which connects Azerbaijan to Turkey as well as to Nakhchivan, will be named the Trump Route for International Peace and Prosperity. The US has secured a 99-year development lease for the route. Planned infrastructure includes highways, railways, pipelines and fibre-optic cables.

Armenia keeps legal control, but gains investment and transit revenue from these endeavours without bearing construction costs. Azerbaijan will gain faster, cheaper export routes for oil, gas and manufactured goods to Turkish and European markets. Armenia also stands to benefit from access to Turkey if the border reopens – the Turks closed it in 1993 in support of Azerbaijan.

Armenia and Azerbaijan have signed separate bilateral agreements with the US on energy, technology and infrastructure, signalling a parallel push to modernise their economies as they normalise relations. Georgia, traditionally the most pro-western and strategically vital state in the South Caucuses, has been sidelined by this arrangement. This is a consequence of its more pro-Russia stance.

---

Read more:
Georgia: how democracy is being eroded fast as government shifts towards Russia

---

The Washington summit has capped years of intermittent mediation attempts. What set this round apart was sustained, high-level US engagement. The Trump administration sent envoys repeatedly, kept negotiations focused on solvable issues, and re-framed the transit corridor as a shared commercial venture.

US involvement is also a built-in guarantee. By taking a long-term stake in the corridor’s development, Washington has an interest in ensuring the agreement is implemented and respected. For Armenia, US backing offers reassurance against renewed coercion from Azerbaijan backed by Turkey. And it opens the door for Azerbaijan to forge deeper ties with the west during a period of bad relations with Russia.

Hurdles ahead

Despite the celebratory signing, the peace deal faces significant hurdles. The agreement sidesteps the plight of Armenian prisoners of war and detainees still held in Azerbaijan. It also ignores the right of return for over 110,000 Armenian civilians who were forcefully expelled from Nagorno-Karabakh. Armenian opposition and diaspora groups have criticised the accord for “sidelining justice”.

Political challenges inside Armenia further cloud the deal’s future. Azerbaijan’s president, Ilham Aliyev, has demanded that Armenia amend its constitution to renounce any territorial claims – specifically removing the 1990 declaration of independence that implied Nagorno-Karabakh is part of Armenia. Baku insists this change is a prerequisite for a “final” peace treaty.

Such external pressure is deeply sensitive. Pashinyan has agreed in principle that Armenia needs a new constitution by 2027 to reflect post-war realities. But if the alterations are perceived as capitulation to Azerbaijani diktat, the domestic backlash could be intense.

The Armenian opposition – already angered by the loss of Karabakh – will likely seize on any constitutional concessions as evidence of national humiliation. With parliamentary elections on the horizon in 2026, Pashinyan’s rivals are positioning to campaign against the peace deal.

They argue that his western-leaning “peace agenda” endangers Armenia’s sovereignty and security. Some have hinted they would reject or renegotiate the agreement if they come to power. Pashinyan’s party was polling poorly earlier in 2025, and recent local elections saw gains for pro-Russian figures, suggesting a volatile electorate.

Armenia’s security services have warned of possible foreign interference and destabilisation efforts as the elections approach. Moscow, in particular, could covertly back Pashinyan’s hardline opponents or spread disinformation to sway the vote, hoping to install a more Russia-aligned leadership that might undermine the deal.

The Washington framework has opened a path to peace. But the coming months and years will determine whether pragmatic interests can triumph over entrenched mistrust.

To succeed, Armenia and Azerbaijan must navigate a minefield of unresolved disputes and political minefields at home, all under the gaze of regional powers uneasy about their changing environment. Washington and Brussels will need to remain engaged, to guarantee compliance and help deliver early economic gains that reinforce peace.

If either side reneges – be it through renewed demands, slow-rolling implementation or back-channel interference – hard-won progress could quickly unravel. This historic breakthrough thus marks not an endpoint but the start of a delicate balancing act.

Brian Brivati does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

– ref. Will Trump’s deal between Armenia and Azerbaijan lead to lasting peace? – https://theconversation.com/will-trumps-deal-between-armenia-and-azerbaijan-lead-to-lasting-peace-262889

Source: The Conversation – UK – By Alison Clare, Senior Research Associate, Translational Health Sciences and Ophthalmology, University of Bristol

Gene therapies hold immense promise for treating sight loss. These therapies use a modified, harmless virus to deliver therapeutic genes directly to diseased cells, helping them to function normally again.

But numerous clinical trials have found that gene therapy causes serious side-effects in some patients because their immune system recognises the virus and attacks it.

So to improve safety and efficacy of gene therapy in the eye, my colleagues and I wanted to understand more about this immune response so we can someday prevent it from happening.

We discovered that old female mice were more vulnerable to experiencing a damaging side-effect from gene therapy, compared to both male mice and young female mice. This reaction was directly related to differences in the way the immune systems of old female mice functioned.

To conduct our study, we gave both male and female mice the gene therapy, which was delivered into the eye. The therapy was tested on young, middle-aged and old mice.

We found that in young mice, females had increased immune activation – even from a lower dose of gene therapy. A similar finding was also recently observed in human blood samples – with women’s immune cells exhibiting greater amounts of inflammation, a sign these immune cells were mounting an attack against the therapy.

Our research went on to show that age was also associated with a stronger inflammatory response to the gene therapy. This was true for both old male and female mice. The inflammatory response lasted longer in the older mice, too.

When we looked more closely at a specific type of immune cell that’s found in the brain and eye, we saw that in older female mice these cells showed signs of both an earlier stress response and stronger inflammatory reaction compared to younger mice and male mice. This reaction was also linked to signs of tissue degeneration.

Together, these findings suggest that women, particularly older women, could be at greater risk of harmful reactions to gene therapy – especially at the doses needed for these therapies to work.

Although our study was conducted in mice, it’s not the first research to show that immune response differences can affect the way men and women react to certain treatments.

Another research group also showed that female mice mounted a stronger response against a gene therapy – recognising it as foreign and removing it. This reduced the amount of therapy delivered successfully to females compared to males.

Treatments for conditions such as arthritis are another example of the way women’s immune response can affect how they respond to treatment. These immunotherapies work better in men compared to women. Some scientists believe this is because women’s immune systems are more likely to recognise the drug as foreign and remove it.

Sex differences and immune function

There’s one key reason men’s and women’s immune systems may respond differently to the same treatment. Women’s immune systems are generally more reactive than men’s to anything unfamiliar.

The types of immune cells that respond the strongest and fastest to a foreign substance are different for men and women. This is because sex hormones – primarily oestrogen for females and testosterone for males – directly affect the way these cells behave.

The X chromosome also plays a role in immune response, as it contains a greater number of immune-related genes compared to the Y chromosome. Females have two X chromosomes, while males have one X and one Y chromosome. These differences will affect how well men and women respond to treatments.

---

Read more:
How biological differences between men and women alter immune responses – and affect women’s health

---

Age further affects how the immune system acts – and how the body responds to different treatments.

As we get older, our immune cells lose their ability to recognise and remove foreign pathogens – though these cells still continue to stimulate inflammation. This leads to a persistent inflammatory state, which is thought to be involved in many age-related conditions – including cardiovascular disease and neurodegeneration.

Differences in immune cell function also become more evident for men and women after the age of 65.

In older men, their inflammatory immune cells are more active after the age of 65, while their adaptive immune cells (which coordinate the recognition and removal of foreign pathogens) are less active.

But as women age, their adaptive immune cell activity can stay the same. Having a stronger adaptive immune response increases the risk of autoimmune conditions – a condition that has been linked to certain neurodegenerative diseases.

These differences help explain why vaccines are less effective for older men because they have fewer functioning adaptive immune cells. They may also help to explain why the older female mice in our study had adverse reactions to the gene therapy, as their immune cells are more primed to attack.

Women have historically been underrepresented in biomedical research. Modelling everything on males has created a data gap in clinical translation, causing harm. For instance, women have nearly twice as many adverse reactions to a drug compared to men.

But studies like ours are helping to provide important insight into why certain medications are less effective in women – and how the immune system is implicated. Crucially, these findings can also help us identify new targets to explore for future treatments.

Alison Clare has received funding from the Wellcome Trust and the Medical Research Council. Her position is currently funded by National Institute for Health and Care Research (NIHR) Biomedical Research Center based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.

– ref. Gene therapy can be less effective in women – and my research in mice brings us one step closer to understanding why – https://theconversation.com/gene-therapy-can-be-less-effective-in-women-and-my-research-in-mice-brings-us-one-step-closer-to-understanding-why-258135